18FDG PET-CT早期预测局部晚期直肠癌术前放化疗1周后的组织病理反应:一项前瞻性临床验证研究

IF 3.3 2区 医学 Q2 ONCOLOGY
Yulia Kundel, Zoya Cohen, Noa Gordon, Aaron Sulkes, Sara Morgenstern, Gali Perl, Nir Wasserberg, David Groshar, Hanna Bernstine, Baruch Brenner
{"title":"18FDG PET-CT早期预测局部晚期直肠癌术前放化疗1周后的组织病理反应:一项前瞻性临床验证研究","authors":"Yulia Kundel, Zoya Cohen, Noa Gordon, Aaron Sulkes, Sara Morgenstern, Gali Perl, Nir Wasserberg, David Groshar, Hanna Bernstine, Baruch Brenner","doi":"10.1186/s13014-025-02703-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Neoadjuvant (preoperative) radiochemotherapy (nRCT) is a standard of care in locally advanced rectal cancer (LARC). Several studies have shown that the decline in <sup>18</sup>FDG uptake after 2 weeks of nRCT compared with the baseline, i.e. the tumor's metabolic response, may correlate with histopathological response. However, our previous prospective study suggested that the tumor's histopathological response could be predicted by the metabolic response already observed after 1 week of nRCT. The current study was undertaken to validate these findings.</p><p><strong>Methods: </strong>Thirty-eight patients with LARC who received standard nRCT followed by radical surgery were enrolled. Metabolic response, evaluated by the percent of change in maximum standardized uptake value (ΔSUVmax%), measured by PET-CT imaging at baseline and on day 8 of nRCT, was compared with the histopathological response at surgery. Histopathological response was assessed by pathological complete response (pCR) and, when possible, by tumor regression grade (TRG). We also examined the association of baseline and second PET-CT parameters with pCR and TRG at surgery.</p><p><strong>Trial registration: </strong>0239-07-RMC, registration date: 21/08/2007.</p><p><strong>Results: </strong>Neither pCR nor TRG were associated with any change in PET-CT parameters after 1 week of treatment. Baseline metabolic tumor volume (MTV) was the only PET-CT parameter with a statistically significant association with pCR (p = 0.002), but not with TRG (p = 0.08).</p><p><strong>Conclusions: </strong>A decrease in SUVmax after 1 week of nRCT for LARC failed to predict the achievement of pCR or TRG in the post-nRCT surgical specimen, underlining the importance of validation clinical trials. Nonetheless, our findings on the correlation between baseline MTV and histopathological response can, if confirmed, be a useful tool for treatment selection. Validation in a larger independent cohort is planned.</p>","PeriodicalId":49639,"journal":{"name":"Radiation Oncology","volume":"20 1","pages":"121"},"PeriodicalIF":3.3000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12317454/pdf/","citationCount":"0","resultStr":"{\"title\":\"Early prediction of histopathological response of locally advanced rectal cancer after 1 week of preoperative radiochemotherapy using <sup>18</sup>FDG PET-CT imaging: a prospective clinical validation study.\",\"authors\":\"Yulia Kundel, Zoya Cohen, Noa Gordon, Aaron Sulkes, Sara Morgenstern, Gali Perl, Nir Wasserberg, David Groshar, Hanna Bernstine, Baruch Brenner\",\"doi\":\"10.1186/s13014-025-02703-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Neoadjuvant (preoperative) radiochemotherapy (nRCT) is a standard of care in locally advanced rectal cancer (LARC). Several studies have shown that the decline in <sup>18</sup>FDG uptake after 2 weeks of nRCT compared with the baseline, i.e. the tumor's metabolic response, may correlate with histopathological response. However, our previous prospective study suggested that the tumor's histopathological response could be predicted by the metabolic response already observed after 1 week of nRCT. The current study was undertaken to validate these findings.</p><p><strong>Methods: </strong>Thirty-eight patients with LARC who received standard nRCT followed by radical surgery were enrolled. Metabolic response, evaluated by the percent of change in maximum standardized uptake value (ΔSUVmax%), measured by PET-CT imaging at baseline and on day 8 of nRCT, was compared with the histopathological response at surgery. Histopathological response was assessed by pathological complete response (pCR) and, when possible, by tumor regression grade (TRG). We also examined the association of baseline and second PET-CT parameters with pCR and TRG at surgery.</p><p><strong>Trial registration: </strong>0239-07-RMC, registration date: 21/08/2007.</p><p><strong>Results: </strong>Neither pCR nor TRG were associated with any change in PET-CT parameters after 1 week of treatment. Baseline metabolic tumor volume (MTV) was the only PET-CT parameter with a statistically significant association with pCR (p = 0.002), but not with TRG (p = 0.08).</p><p><strong>Conclusions: </strong>A decrease in SUVmax after 1 week of nRCT for LARC failed to predict the achievement of pCR or TRG in the post-nRCT surgical specimen, underlining the importance of validation clinical trials. Nonetheless, our findings on the correlation between baseline MTV and histopathological response can, if confirmed, be a useful tool for treatment selection. Validation in a larger independent cohort is planned.</p>\",\"PeriodicalId\":49639,\"journal\":{\"name\":\"Radiation Oncology\",\"volume\":\"20 1\",\"pages\":\"121\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12317454/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Radiation Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s13014-025-02703-x\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiation Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13014-025-02703-x","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:新辅助(术前)放化疗(nRCT)是局部晚期直肠癌(LARC)的标准治疗方法。几项研究表明,与基线相比,nRCT 2周后18FDG摄取的下降,即肿瘤的代谢反应,可能与组织病理反应有关。然而,我们之前的前瞻性研究表明,肿瘤的组织病理学反应可以通过nRCT 1周后已经观察到的代谢反应来预测。目前的研究是为了验证这些发现。方法:选取38例LARC患者,接受标准nRCT后行根治性手术。代谢反应,通过基线和nRCT第8天PET-CT成像测量的最大标准化摄取值变化百分比(ΔSUVmax%)来评估,与手术时的组织病理反应进行比较。通过病理完全缓解(pCR)和肿瘤消退等级(TRG)评估组织病理反应。我们还检查了基线和第二次PET-CT参数与手术时pCR和TRG的关系。试验注册:0239-07-RMC,注册日期:21/08/2007。结果:治疗1周后,pCR和TRG均与PET-CT参数变化无关。基线代谢肿瘤体积(MTV)是唯一与pCR有统计学意义相关的PET-CT参数(p = 0.002),但与TRG无统计学意义(p = 0.08)。结论:LARC患者nRCT 1周后SUVmax的下降并不能预测nRCT后手术标本中pCR或TRG的实现,强调了验证性临床试验的重要性。尽管如此,我们关于基线MTV和组织病理反应之间的相关性的发现,如果得到证实,可以成为治疗选择的有用工具。计划在更大的独立队列中进行验证。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Early prediction of histopathological response of locally advanced rectal cancer after 1 week of preoperative radiochemotherapy using <sup>18</sup>FDG PET-CT imaging: a prospective clinical validation study.

Early prediction of histopathological response of locally advanced rectal cancer after 1 week of preoperative radiochemotherapy using <sup>18</sup>FDG PET-CT imaging: a prospective clinical validation study.

Early prediction of histopathological response of locally advanced rectal cancer after 1 week of preoperative radiochemotherapy using <sup>18</sup>FDG PET-CT imaging: a prospective clinical validation study.

Early prediction of histopathological response of locally advanced rectal cancer after 1 week of preoperative radiochemotherapy using 18FDG PET-CT imaging: a prospective clinical validation study.

Background: Neoadjuvant (preoperative) radiochemotherapy (nRCT) is a standard of care in locally advanced rectal cancer (LARC). Several studies have shown that the decline in 18FDG uptake after 2 weeks of nRCT compared with the baseline, i.e. the tumor's metabolic response, may correlate with histopathological response. However, our previous prospective study suggested that the tumor's histopathological response could be predicted by the metabolic response already observed after 1 week of nRCT. The current study was undertaken to validate these findings.

Methods: Thirty-eight patients with LARC who received standard nRCT followed by radical surgery were enrolled. Metabolic response, evaluated by the percent of change in maximum standardized uptake value (ΔSUVmax%), measured by PET-CT imaging at baseline and on day 8 of nRCT, was compared with the histopathological response at surgery. Histopathological response was assessed by pathological complete response (pCR) and, when possible, by tumor regression grade (TRG). We also examined the association of baseline and second PET-CT parameters with pCR and TRG at surgery.

Trial registration: 0239-07-RMC, registration date: 21/08/2007.

Results: Neither pCR nor TRG were associated with any change in PET-CT parameters after 1 week of treatment. Baseline metabolic tumor volume (MTV) was the only PET-CT parameter with a statistically significant association with pCR (p = 0.002), but not with TRG (p = 0.08).

Conclusions: A decrease in SUVmax after 1 week of nRCT for LARC failed to predict the achievement of pCR or TRG in the post-nRCT surgical specimen, underlining the importance of validation clinical trials. Nonetheless, our findings on the correlation between baseline MTV and histopathological response can, if confirmed, be a useful tool for treatment selection. Validation in a larger independent cohort is planned.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Radiation Oncology
Radiation Oncology ONCOLOGY-RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
CiteScore
6.50
自引率
2.80%
发文量
181
审稿时长
3-6 weeks
期刊介绍: Radiation Oncology encompasses all aspects of research that impacts on the treatment of cancer using radiation. It publishes findings in molecular and cellular radiation biology, radiation physics, radiation technology, and clinical oncology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信